Iodine‑131 metabolic radiotherapy leads to cell death and genomic alterations through NIS overexpression on cholangiocarcinoma

Abstract

Cholangiocarcinoma (CC) is an aggressive liver tumor with limited therapeutic options. Natrium-iodide symporter (NIS) mediates the uptake of iodine by the thyroid, representing a key component in metabolic radiotherapy using iodine-131 (131 I) for the treatment of thyroid cancer. NIS expression is increased in CC, providing the opportunity for a novel therapeutic approach for this type of tumor. Thus, in this study, we aimed to evaluate therapeutic efficacy of 131 I in two human CC cell lines. Uptake experiments analyzed the 131 I uptake profiles of the tumor cell lines under study. The cells were irradiated with various doses of 131 I to evaluate and characterize the effects of metabolic radiotherapy. NIS protein expression was assessed by immunofluorescence methods. Cell survival was evaluated by clonogenic assay and flow cytometry was used to assess cell viability, and the type of death and alterations in the cell cycle. The genomic and epigenetic characterization of both CC cells was performed before and after irradiation. NIS gene expression was evaluated in the CC cells by RT-qPCR. The results revealed that CC cells had a higher expression of NIS. 131 I induced a decrease in cell survival in a dose-dependent manner. With the increasing irradiation dose, a decrease in cell viability was observed, with a consequent increase in cell death by initial apoptosis. Karyotype and array comparative genomic hybridization (aCGH) analyses revealed that both CC cell lines were near-triploid with several numerical and structural chromosomal rearrangements. NIS gene expression was increased in the TFK-1 and HuCCT1 cells in a time-dependent manner. On the whole, the findings of this study demonstrate that the presence of NIS in cholangiocarcinoma cell lines is crucial for the decreased cell viability and survival observed following the exposure of cholangiocarcinoma cells to 131 I.

Matrices and Affinity Ligands for Antibody Purification and Corresponding Applications in Radiotherapy

“…In particular, metabolic radiotherapy is a type of radiotherapy treatment that is carried out by introducing radioactive compounds into the body. The radioactive compounds are metabolized only at the target location to destroy the malignant cells without affecting healthy tissues [ 134 , 135 ]. Moreover, the applications of chromatographic matrices and affinity ligands in radiotherapy may be limited and do not represent a therapeutic opportunity for all cancers at present.…”

Anti-EpCAM Functionalized I-131 Radiolabeled Biomimetic Nanocarrier Sodium/Iodide-Symporter-Mediated Breast-Cancer Treatment

“…In nuclear medicine, the radiopharmaceutical 131 I has been the principal diagnostic and therapeutic agent for thyroid cancer and the first theranostic agent, as it emits both 90% beta particles (therapeutic) to destroy cancer cells and 10% gamma particles (diagnostic) [ 3 ]. Currently, 131 I is mainly used for thyroid treatment because the thyroid gland has a sodium-iodide symporter (NIS), a glycosylate-containing integral membrane protein that mediates intracellular iodine transport and regulates thyroid 131 I accumulation [ 3 ]. Additionally, NIS is also expressed in mammary glands, the ciliary body of the eye, the choroid plexus, the stomach parietal cells, and salivary glands.…”

Effectiveness and Safety of Levothyroxine Tablets Combined with Iodine-131 in the Treatment of Thyroid Cancer

“…It effectively improves the postoperative prognosis of patients and prevents metastasis and recurrence. It is currently the preferred postoperative treatment for differentiated thyroid cancer [ 6 , 7 ]. This study recruited 70 patients with thyroid cancer receiving radical thyroidectomy in our hospital from July 2019 to April 2020 to explore the effectiveness of levothyroxine tablets combined with iodine-131 in thyroid cancer patients after radical thyroidectomy and its effect on serum Tg and TgAb levels to provide a reference for clinical practice.…”